Dexamethasone: Benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: A study on myocardial, pulmonary, renal, intestinal, and hepatic injury

Chest

Volumn 128, Issue 4, 2005, Pages 2677-2687

  Morariu, Aurora M ^a   Loef, Berthus G ^a   Aarts, Leon P H J ^a   Rietman, Gerrit W ^a   Rakhorst, Gerhard ^a   Van Oeveren, Wim ^a   Epema, Anne H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Coronary artery bypass grafting; Dexamethasone; Fatty acid binding proteins; Mast cell tryptase

Indexed keywords

ACETYLGLUCOSAMINIDASE; C REACTIVE PROTEIN; CREATINE KINASE MB; CYTOKINE; DEXAMETHASONE; FATTY ACID BINDING PROTEIN; GLUTATHIONE TRANSFERASE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TROPONIN I; TRYPTASE;

ADULT; AGED; ANESTHESIA INDUCTION; CARDIOPULMONARY ARREST; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE INJURY; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INTENSIVE CARE UNIT; INTESTINE INJURY; KIDNEY INJURY; LIVER INJURY; LUNG INJURY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 27144550123     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.2677     Document Type: Conference Paper

References (47)

1. Chaney MA. Corticosteroids and cardiopulmonary bypass: a review of clinical investigations. Chest 2002; 121:921-931
2. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment; an update. Eur J Cardiothorac Surg 2002; 21:232-244
3. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications; part 1. Circulation 2001; 104:2981-2989
4. Ng CS, Wan S, Yim AP, et al. Pulmonary dysfunction after cardiac surgery. Chest 2002; 121:1269-1277
5. Halm MA. Acute gastrointestinal complications after cardiac surgery. Am J Crit Care 1996; 5:109-118
6. Nakamura K, Harasaki H, Fukumura F, et al. Comparison of pulsatile and non-pulsatile cardiopulmonary bypass on regional renal blood flow in sheep. Scand Cardiovasc J 2004; 38:59-63
7. Jansen NJ, van Oeveren W, van den Broek L, et al. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 102:515-525
8. El Azab SR, Rosseel PM, de Lange JJ, et al. Dexamethasone decreases the pro- to anti-inflammatory cytokine ratio during cardiac surgery. Br J Anaesth 2002; 88:496-501
9. von Spiegel T, Giannaris S, Wietasch GJ, et al. Effects of dexamethasone on intravascular and extravascular fluid balance in patients undergoing coronary bypass surgery with cardiopulmonary bypass. Anesthesiology 2002; 96:827-834
10. Kawamura T, Inada K, Okada H, et al. Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery. Can J Anaesth 1995; 42:399-403
11. Toft P, Christiansen K, Tonnesen E, et al. Effect of methyl-prednisolone on the oxidative burst activity, adhesion molecules and clinical outcome following open heart surgery, Scand Cardiovasc J 1997; 31:283-288
12. Chaney MA, Durazo-Arvizu RA, Nikolov MP, et al. Methyl-prednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation. J Thorac Cardiovasc Surg 2001; 121:561-569
13. Chaney MA, Nikolov MP, Blakeman BP, et al. Hemodynamic effects of methylprednisolone in patients undergoing cardiac operation and early extubation. Ann Thorac Surg 1999; 67:1006-1011
14. Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia 2004; 59: 695-703
15. van der Maaten JM, Epema AH, Huet RC, et al. The effect of midazolam at two plasma concentrations of hemodynamics and sufentanil requirement in coronary artery surgery. J Cardiothorac Vasc Anesth 1996; 10:356-363
16. Lockwood TD, Bosmann HB. The use of urinary N-acetyl-β- glucosaminidase in human renal toxicology: II. Partial biochemical characterization and excretion in humans and release from the isolated perfused rat kidney. Toxicol Appl Pharmacol 1979; 49:323-336
17. Gollin G, Marks C, Marks W. Intestinal fatty acid binding protein in serum and urine reflects early ischemic injury to the small bowel. Surgery 1993; 113:545-551
18. Beckett GJ, Hayes JD. Glutathione S-transferases: biomedical applications. Adv Clin Chem 1993; 30:281-380
19. Loef BG, Henning RH, Epema AH, et al. Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass. Br J Anaesth 2004; 93:793-798
20. Veerkamp JH, Paulussen RJ, Peeters RA, et al. Detection, tissue distribution and (sub)cellular localization of fatty acid-binding protein types. Mol Cell Biochem 1990; 98:11-18
21. Yoshimoto K, Tanaka T, Somiya K, et al. Human heart-type cytoplasmic fatty acid-binding protein as an indicator of acute myocardial infarction. Heart Vessels 1995; 10:304-309
22. Petzold T, Feindt P, Sunderdiek U, et al. Heart-type fatty acid binding protein (hFABP) in the diagnosis of myocardial damage in coronary artery bypass grafting. Eur J Cardiothorac Surg 2001; 19:859-864
23. Suzuki K, Sawa Y, Kadoba K, et al. Early detection of cardiac damage with heart fatty acid-binding protein after cardiac operations. Ann Thorac Surg 1998; 65:54-58
24. Swaanenburg JC, Loef BG, Volmer M, et al. Creatine kinase MB, troponin I, and troponin T release patterns after coronary artery bypass grafting with or without cardiopulmonary bypass and after aortic and mitral valve surgery. Clin Chem 2001; 47:584-587
25. Lam K, Borkan S, Claffey K, et al. Properties and differential regulation of two fatty acid binding proteins in the rat kidney. J Biol Chem 1988; 263:15762-15768
26. Gok MA, Pelzers M, Glatz JF, et al. Do tissue damage biomarkers used to assess machine-perfused NHBD kidneys predict long-term renal function post-transplant? Clin Chim Acta 2003; 338:33-43
27. Pelsers MM, Namiot Z, Kisielewski W, et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine: tissue distribution and clinical utility. Clin Biochem 2003; 36:529-535
28. Lieberman JM, Sacchettini J, Marks C, et al. Human intestinal fatty acid binding protein: report of an assay with studies in normal volunteers and intestinal ischemia. Surgery 1997; 121:335-342
29. Holmes JH IV, Lieberman JM, Probert CB, et al. Elevated intestinal fatty acid binding protein and gastrointestinal complications following cardiopulmonary bypass: a preliminary analysis. J Surg Res 2001; 100:192-196
30. Sinclair DG, Haslam PL, Quinlan GJ, et al. The effect of cardiopulmonary bypass on intestinal and pulmonary endothelial permeability. Chest 1995; 108:718-724
31. Ohri SK, Bjarnason I, Pathi V, et al. Cardiopulmonary bypass impairs small intestinal transport and increase gut permeability. Ann Thorac Surg 1993; 55:1080-1086
32. Wan S, LeClerc JL, Huynh CH, et al. Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass? J Thorac Cardiovasc Surg 1999; 117:1004-1008
33. Lieberman JM, Marks WH, Cohn S, et al. Organ failure, infection, and the systemic inflammatory response syndrome are associated with elevated levels of urinary intestinal fatty acid binding protein: study of 100 consecutive patients in a surgical intensive care unit. J Trauma 1998; 45:900-906
34. Kumle B, Boldt J, Suttner SW, et al. Influence of prolonged cardiopulmonary bypass times on splanchnic perfusion and markers of splanchnic organ function. Ann Thorac Surg 2003; 75:1558-1564
35. Bar-Yosef S, Mathew JP, Newman MF, et al. Prevention of cerebral hyperthermia during cardiac surgery by limiting on-bypass rewarming in combination with post-bypass body surface warming: a feasibility study. Anesth Analg 2004; 99:641-646
36. Bronicki RA, Backer CL, Baden HP, et al. Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2000; 69:1490-1495
37. Withington DE, Aranda JV. Histamine release during cardiopulmonary bypass in neonates and infants. Can J Anaesth 1997; 44:610-616
38. van Overveld FJ, De Jongh RF, Jorens PG, et al. Pretreatment with methylprednisolone in coronary artery bypass grafting influences the levels of histamine and tryptase in serum but not in bronchoalveolar lavage fluid. Clin Sci (Lond) 1994; 86:49-53
39. Wang HW, McNeil HP, Husain A, et al. Delta tryptase is expressed in multiple human tissues, and a recombinant form has proteolytic activity. J Immunol 2002; 169:5145-5152
40. Ehara T, Shigematsu H. Mast cells in the kidney. Nephrology (Carlton) 2003; 8:130-138
41. Huang C, Friend DS, Qiu WT, et al. Induction of a selective and persistent extravasation of neutrophils into the peritoneal cavity by the tryptase mouse mast cell protease 6. J Immunol 1998; 160:1910-1919
42. He S, Walls AF. Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. Eur J Pharmacol 1997; 328:89-97
43. Yousif MH, Oriowo MA, Cherian A, et al. Histaniine-induced vasodilatation in the perfused mesenteric arterial bed of diabetic rats. Vasc Pharmacol 2002; 39:287-292
44. Vanhorebeek I, De Vos R, Mesotten D, et al. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 2005; 365:53-59
45. Bohlen HG, Lash JM. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol 1993; 265:H219-H225
46. Jin JS, Bohlen HG. Non-insulin-dependent diabetes and hyperglycemia impair rat intestinal flow-mediated regulation. Am J Physiol 1997; 272:H728-H734
47. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367